|
|
|
| 
|
|
|
My Recent Searches
|
|
|
|
|
|
|
|
|
Codiak Biosciences, Inc. (CDAK) |
|
|
$0.00 0.00 (0.00%) as of 4:30 Tue 11/30
|
|
Download |
|
|
| |
| |
| Exchange: |
N/A |
| Security
Type: |
N/A |
| Shares
Out: |
18,590,000 |
| Market
Cap: |
N/A |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$ - $ |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Codiak BioSciences is a clinical-stage biopharmaceutical company focused on the development of exosome-based therapeutics. One of Co.'s clinical stage programs, exoSTING, is an exosome therapeutic candidate delivering its proprietary STING agonist while expressing high levels of Prostaglandin F2 receptor negative regulator (PTGFRN) on the exosome surface to facilitate specific uptake in tumor-resident antigen-presenting cells. Co.'s other clinical stage program, exoIL-12, displays IL-12 in an active form on the surface of the engineered exosome. Co.'s third clinical stage program, exoASO-STAT6, overexpresses PTGFRN to selectively target uptake in M2-polarized tumor-associated-macrophages.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
10,933,333 |
| Total Buy Value |
$0 |
$0 |
$0 |
$7,500,000 |
| Total People Bought |
0 |
0 |
0 |
3 |
| Total Buy Transactions |
0 |
0 |
0 |
3 |
| Total Shares Sold |
0 |
0 |
0 |
129,081 |
| Total Sell Value |
$0 |
$0 |
$0 |
$66,165 |
| Total People Sold |
0 |
0 |
0 |
6 |
| Total Sell Transactions |
0 |
0 |
0 |
24 |
| End Date |
2024-03-07 |
2023-12-05 |
2023-06-06 |
2022-06-06 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Barna Nicole |
See Remarks |
• – – |
2022-01-20 |
4 |
B |
$7.37 |
$49,978 |
D/D |
6,781 |
6,781 |
2.74 |
- |
|
| Sathyanarayanan Sriram |
Chief Scientific Officer |
• – – |
2021-08-09 |
4 |
AS |
$21.31 |
$27,965 |
D/D |
(1,300) |
0 |
|
- |
|
| Sathyanarayanan Sriram |
Chief Scientific Officer |
• – – |
2021-08-09 |
4 |
OE |
$3.29 |
$4,277 |
D/D |
1,300 |
1,300 |
|
- |
|
| Sathyanarayanan Sriram |
Chief Scientific Officer |
• – – |
2021-08-06 |
4 |
AS |
$20.16 |
$26,206 |
D/D |
(1,300) |
0 |
|
- |
|
| Sathyanarayanan Sriram |
Chief Scientific Officer |
• – – |
2021-08-06 |
4 |
OE |
$3.29 |
$4,277 |
D/D |
1,300 |
1,300 |
|
- |
|
| Sorensen Benny |
See Remarks |
• – – |
2021-06-08 |
4 |
AS |
$25.57 |
$219,016 |
D/D |
(8,533) |
0 |
|
- |
|
| Sorensen Benny |
See Remarks |
• – – |
2021-06-08 |
4 |
OE |
$3.29 |
$28,074 |
D/D |
8,533 |
8,533 |
|
- |
|
| Konstantinov Konstantin |
Chief Technology Officer |
• – – |
2021-06-08 |
4 |
AS |
$25.53 |
$186,276 |
D/D |
(7,276) |
0 |
|
- |
|
| Konstantinov Konstantin |
Chief Technology Officer |
• – – |
2021-06-08 |
4 |
OE |
$3.29 |
$23,938 |
D/D |
7,276 |
7,276 |
|
- |
|
| Morrison Briggs |
Director |
– • – |
2021-02-17 |
4 |
B |
$21.00 |
$99,981 |
D/D |
4,761 |
4,761 |
2.39 |
- |
|
| Alaska Permanent Fund Corp |
|
• • • |
2020-10-16 |
4 |
B |
$15.00 |
$3,525,000 |
I/I |
235,000 |
4,512,895 |
0.01 |
- |
|
| Alaska Permanent Fund Corp |
|
• • • |
2020-10-16 |
4 |
A |
$0.00 |
$0 |
I/I |
4,213,932 |
4,512,895 |
|
- |
|
| Williams Douglas E |
President & CEO |
• • – |
2020-10-16 |
4 |
A |
$0.00 |
$0 |
D/D |
9,585 |
9,585 |
|
- |
|
| Arch Venture Partners Viii, L.p. |
10% Owner |
– – • |
2020-10-16 |
4 |
B |
$15.00 |
$3,525,000 |
I/I |
235,000 |
2,503,903 |
1.5 |
- |
|
| Arch Venture Partners Viii, L.p. |
10% Owner |
– – • |
2020-10-16 |
4 |
A |
$0.00 |
$0 |
I/I |
3,555,135 |
1,350,195 |
|
- |
|
| Afeyan Noubar |
10% Owner |
– – • |
2020-10-16 |
4 |
B |
$15.00 |
$2,475,000 |
I/I |
165,000 |
1,143,177 |
1.5 |
- |
|
| Afeyan Noubar |
10% Owner |
– – • |
2020-10-16 |
4 |
A |
$0.00 |
$0 |
I/I |
1,956,354 |
978,177 |
|
- |
|
| Gillis Steven |
Director |
– • – |
2020-10-16 |
4 |
B |
$15.00 |
$3,525,000 |
I/I |
235,000 |
2,503,903 |
2.1 |
- |
|
| Gillis Steven |
Director |
– • – |
2020-10-16 |
4 |
A |
$0.00 |
$0 |
I/I |
2,204,940 |
2,268,903 |
|
- |
|
| Melas Kyriazi Theo |
Director |
– • – |
2020-10-13 |
4 |
B |
$15.00 |
$99,000 |
D/D |
6,600 |
6,600 |
2.39 |
- |
|
| Alaska Permanent Fund Corp |
|
– – • |
2020-10-13 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
63,963 |
|
- |
|
| Afeyan Noubar |
10% Owner |
– – • |
2020-10-13 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
485,949 |
|
- |
|
| Arch Venture Partners Viii, L.p. |
10% Owner |
– – • |
2020-10-13 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
63,963 |
|
- |
|
| Gillis Steven |
Director |
– • – |
2020-10-13 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
63,963 |
|
- |
|
| Lander Eric S |
Director |
– • – |
2020-10-13 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
230,267 |
|
- |
|
76 Records found
|
|
Page 3 of 4 |
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
| |
OE |
- Options Exercised |
A |
- Acquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
